Anthelmintic Drug Class List

Drugs in Drug Class: Anthelmintic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Elizabeth	ALBENDAZOLE	albendazole	TABLET;ORAL	208094-001	May 20, 2019	AB	RX	No	No
Alembic	ALBENDAZOLE	albendazole	TABLET;ORAL	215652-001	Sep 4, 2024	AB	RX	No	No
Cipla Ltd	ALBENDAZOLE	albendazole	TABLET;ORAL	210434-001	Sep 21, 2018		DISCN	No	No
Dr Reddys	ALBENDAZOLE	albendazole	TABLET;ORAL	211034-001	Jan 26, 2021	AB	RX	No	Yes
Edenbridge Pharms	ALBENDAZOLE	albendazole	TABLET;ORAL	211117-001	May 14, 2019	AB	RX	No	No
Msn	ALBENDAZOLE	albendazole	TABLET;ORAL	213435-001	Jan 21, 2021	AB	RX	No	No
Strides Pharma	ALBENDAZOLE	albendazole	TABLET;ORAL	210011-001	Dec 7, 2018		DISCN	No	No

Anthelmintic Market Analysis and Financial Projection

The anthelmintic drugs market is experiencing significant growth driven by rising parasitic infections and technological advancements, while its patent landscape reflects ongoing innovation to address drug resistance and formulation challenges.

---

Market Dynamics

Growth Drivers

• Rising parasitic infections: Over 1.5 billion people globally are affected by soil-transmitted helminths, particularly in low-resource regions with poor sanitation[2][3].
• Veterinary demand: Livestock health initiatives and zoonotic disease prevention are expanding animal health applications[6][12].
• Public health programs: Mass drug administration campaigns in endemic regions (e.g., sub-Saharan Africa, Southeast Asia) drive bulk procurement[2][11].

Market Segmentation

By Drug Class	Class	Key Drugs	Market Share (2022)
Benzimidazoles	Albendazole, Mebendazole	37%[2]
Macrocyclic Lactones	Ivermectin	Fastest-growing[2]
Pyrazinoisoquinolones	Praziquantel	Niche applications

By Application

• Human: Ascariasis, hookworm, trichuriasis[1].
• Veterinary: Livestock deworming accounts for ~45% of revenue[6].

Projected Growth	Source	2024 Valuation	2032 Projection	CAGR
Databridge Market Research[1]	$3.62B	$6.91B	8.42%
Allied Market Research[2]	$1B (2022)	$1.5B	3.8%

Discrepancies stem from differing geographic scopes and inclusion of veterinary vs. human markets.

---

Patent Landscape

Key Innovations

1. Stable formulations:

   • Ivermectin tablets: Patented methods to mitigate hygroscopicity and photodegradation (e.g., PEG-based stabilizers)[4][14].
   • Combination therapies: EP2468096A1 covers mixtures of benzimidazoles with newer anthelmintics to delay resistance[12].

2. Novel delivery systems:

   • Probiotic Bacillus subtilis: Engineered to express Bacillus thuringiensis Cry proteins targeting helminths[10].

3. Broad-spectrum compounds:

   • Patent EP2744495B1 covers levamisole-based formulations with enhanced immune stimulation[13].

Geographic Trends

• Leading filers: U.S. (33%), China (19%), EU (15%)[11].
• Emerging markets: China’s patent filings for soil-transmitted helminths surged post-2010[11].

Challenges

• Resistance: 58% of livestock farms report reduced efficacy of benzimidazoles[6].
• Regulatory barriers: Stringent toxicity requirements delay approvals for combination drugs[6].

---

Competitive Landscape

Major Players

Company	Key Products	Strategic Focus
Merck & Co.	Ivermectin (Stromectol®)	Veterinary formulations
Bayer AG	Praziquantel (Biltricide®)	Schistosomiasis campaigns
Teva Pharmaceuticals	Albendazole generics	Cost-effective production

Emerging Trends

• AI-driven R&D: 33% increase in AI-related pharmaceutical patents since 2018, accelerating drug repurposing[9].
• Non-profit partnerships: Universities and NGOs file 28% of recent patents, focusing on neglected tropical diseases[11].

---

Future Outlook

The market will hinge on balancing affordability with innovation, particularly in regions like Africa and Asia-Pacific where 72% of helminthiasis cases occur[2][7]. Patent expirations (e.g., mebendazole’s core patent in 2025[8]) may boost generics but could exacerbate resistance without novel therapeutic approaches.

"The next decade will require a dual focus: expanding access to existing drugs while investing in next-generation anthelmintics." – Industry Analyst Report[6]

References

1. https://www.databridgemarketresearch.com/reports/global-anthelmintics-market
2. https://www.alliedmarketresearch.com/anthelmintic-drugs-market-A11501
3. https://www.pharmiweb.com/press-release/2024-05-03/anthelmintic-drugs-market-to-surpass-15plus-billion-by-2032-driven-by-38-cagr
4. https://patents.google.com/patent/US7396819B2/en
5. https://www.cognitivemarketresearch.com/anthelmintic-fenbendazole-market-report
6. https://www.giiresearch.com/report/ires1602778-anthelmintic-drugs-market-by-drug-class.html
7. https://www.databridgemarketresearch.com/es/reports/global-anthelmintics-market/market-analysis
8. https://www.drugpatentwatch.com/p/patent/3657267
9. https://ip.com/blog/2025-patent-trends-challenges-and-innovations-shaping-the-future-of-technology/
10. https://pubchem.ncbi.nlm.nih.gov/patent/US-10940170-B2
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5686799/
12. https://patents.google.com/patent/EP2468096A1/en
13. https://patents.google.com/patent/EP2744495B1/en
14. https://patents.google.com/patent/WO2005016357A1/en